Stada Arz first-half 2012 sales rise 7%

German generic and branded drugmaker Stada Arzneimittel (SAZ: GR) reported first-half 2012 financial results, showing that group sales grew 7% year-on-year to 885.2 million euros ($1.09 billion).

Adjusted EBITDA and adjusted earnings per share both rise to 176.7 million euros (+10%) and 1.19 euros (+7%), respectively. One-time special effects in the amount of 25.7 million euros before taxes primarily due to the planned continuation of the cost efficiency program “STADA – build the future”

“In consideration of the recently made acquisitions, we were able to expand our international business activities to a share of nearly three quarters of Group sales, and have thereby again made ourselves a bit more independent of the heavily regulated German market”, explained STADA chairman of the executive board, Hartmut Retzlaff, adding: “Against this backdrop we remain optimistic in our outlook for the current financial year and expect to be able to reach the goals we have set.”